Katie Dennis, MD
Internal Medicine · Lafayette, LANPI 1720474273
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations.
Across 289 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$553
- Novo Nordisk$530
- AstraZeneca$520
- Amgen$442
- Pfizer$328
- AbbVie$226
- plus $2K from 35 others
What the payments were for
- Food & beverage$4,327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 41 | $553 |
| Novo Nordisk | 40 | $530 |
| AstraZeneca | 36 | $520 |
| Amgen | 32 | $442 |
| Pfizer | 17 | $328 |
| AbbVie | 14 | $226 |
| Bayer | 9 | $139 |
| Boehringer Ingelheim | 8 | $129 |
| Daiichi Sankyo Inc. | 6 | $122 |
| Abbott | 8 | $121 |
| Astellas Pharma US Inc | 7 | $114 |
| Novartis | 7 | $103 |
| Exact Sciences | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| GSK | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Amarin Pharma, Inc. | 3 | $50 |
| Dexcom, Inc. | 3 | $48 |
| Lundbeck LLC | 2 | $44 |
| Johnson & Johnson | 3 | $40 |
| Ardelyx, Inc. | 2 | $40 |
| Edwards Lifesciences | 2 | $39 |
| Noven Therapeutics, LLC | 2 | $32 |
| Merck | 2 | $28 |
| Seqirus USA Inc | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 3 | $24 |
| Sanofi Pasteur Inc. | 2 | $24 |
| Biogen | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Convatec Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
How this compares
$4,327 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $97,175 |
| OzempicSemaglutide | 49 | $61,141 |
| JardianceEmpagliflozin | 54 | $55,649 |
| TrulicityDulaglutide | 24 | $33,268 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 58 | $17,685 |
| LinzessLinaclotide | 25 | $16,593 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 30 | $6,606 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,600 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,518 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,301 |
| Rosuvastatin Calcium | 353 | $5,340 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,805 |
| Atorvastatin Calcium | 198 | $3,221 |
| Pantoprazole Sodium | 195 | $2,930 |
| Valsartan | 19 | $2,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $553 | $130,444119 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $129 | $62,16766 claims |
| Novo NordiskOzempic | $530 | $61,14149 claims |
| GSKArexvy, Shingrix, Incruse Ellipta, Breo Ellipta | $68 | $35,396118 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $226 | $19,29174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lafayette
- Bryan LebeanLafayette$53K
- Nethuja SalagundlaLafayette$32K
- Hector RoblesLafayette$19K
- Brad BroussardLafayette$17K
- Juan Perez-RuizLafayette$12K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.